Genomic Answers for Children’s Health Act of 2026
- Sponsor
- Rep. Peters, Scott H. [D-CA-50]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jan 15, 2026
Bottom line
This bill aims to improve access to advanced genetic testing for Medicaid-eligible children by explicitly mandating coverage, preventing payment bundling, and requiring oversight to ensure effective implementation.
What it actually does
This bill amends the Social Security Act to explicitly clarify that whole genome and whole exome sequencing for children with suspected genetic disorders, rare diseases, or conditions of unknown origin is covered under the Medicaid program. It mandates that payment for these services be made separately and not bundled with other medical assistance, and directs the Secretary of Health and Human Services to conduct outreach and report on implementation, alongside a report from the Comptroller General.
Proponents argue
Supporters argue this bill addresses a critical gap in care, enabling earlier diagnosis and more effective treatment for children with complex medical conditions, potentially reducing long-term healthcare costs and significantly improving quality of life. They emphasize that whole genome and exome sequencing can end diagnostic odysseys, providing timely answers for families.
Opponents contend
Potential opponents might raise concerns about the increased costs to state Medicaid programs, the potential for overutilization without clear guidelines, or the administrative burden of implementing new coverage requirements and reporting mandates. Some might argue that existing Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) services already provide sufficient flexibility for such coverage.
The bill is concise and easily readable, allowing for quick comprehension of its core provisions and implications.
Section 2(a)
Mandatory Medicaid Coverage for Whole Genome and Whole Exome Sequencing
This provision amends the Social Security Act to explicitly include whole genome sequencing (WGS) and whole exome sequencing (WES) as covered medical assistance under Medicaid. This coverage is for children suspected of having genetic disorders, rare diseases, or health conditions of unknown origin, such as congenital anomalies or developmental delays, when ordered as a first-tier test by a qualified provider. It also defines these sequencing methods to include analysis, interpretation, and data reports, and allows for testing of first-degree relatives for the primary benefit of the child's diagnosis or treatment.
Supporters argue
Supporters argue this is crucial for ending diagnostic odysseys, leading to earlier interventions, better health outcomes, and potentially reducing overall healthcare costs by avoiding prolonged, ineffective testing. It ensures equitable access to cutting-edge diagnostic tools for vulnerable children.
Critics contend
Critics might express concerns about the financial burden on state Medicaid budgets and the potential for increased utilization without clear, consistent guidelines on when WGS/WES is truly considered a 'first-tier' test.
Tradeoffs
The bill balances the immediate costs of advanced genetic testing against the long-term benefits of early diagnosis, targeted treatment, and improved quality of life for children with rare diseases. It also navigates the tension between state flexibility in Medicaid program design and federal mandates for specific coverage.
Section 2(b)
Prohibiting Bundled Payments for Genomic Sequencing
This section amends the Social Security Act to require that payments for whole genome and whole exome sequencing under Medicaid are made separately and are not bundled as part of payment for any other medical assistance. This ensures that the specific costs associated with these advanced genetic tests are clearly accounted for and reimbursed independently.
Section 2(c)
HHS Outreach, Education, and Reporting on Genomic Sequencing
This provision directs the Secretary of Health and Human Services (HHS) to undertake several activities to promote awareness of and access to WGS/WES under Medicaid. This includes convening national organizations and states to identify implementation challenges and best practices (especially regarding prior authorization), conducting outreach to various stakeholders about EPSDT services, and publishing a report within two years. The report must detail payment amounts, the number of children receiving sequencing, health outcomes, and types of services provided as a result of the sequencing.
Section 2(d)
Comptroller General Report and Recommendations
This section mandates that the Comptroller General (CG) of the United States conduct a comprehensive study within two years of the Act's enactment. The study will collect feedback from stakeholders on experiences accessing WGS/WES, identify barriers, assess changes in care, and evaluate the impact of prior authorization, workforce challenges for genetic counselors, and the alignment of market costs with Medicare fee schedules. The CG will then make recommendations to HHS for improvements based on these findings.
The definition of 'whole genome sequencing and whole exome sequencing' explicitly includes 'any analysis, interpretation, and data report derived from such sequencing' and allows for testing of 'a first degree biological relative or relatives of such individual for the purpose of determining whether 1 or more potentially disease-causing genetic variants are present'.
Section 2(a)(2), new subsection (kk)
Why it matters:This is standard legislative practice to place detailed definitions in a dedicated section, ensuring clarity and comprehensive scope without cluttering the primary operative language.
Case for: Supporters argue that including analysis, interpretation, and relative testing is essential for the clinical utility of WGS/WES, as raw data alone is insufficient for diagnosis and treatment. Testing relatives can significantly aid in confirming diagnoses and understanding inheritance patterns.
Case against: Some might argue that including relative testing could expand costs beyond the primary patient, or that the scope of 'analysis and interpretation' needs further clarification to prevent excessive billing.
Estimated impact: Ensures comprehensive coverage of the entire diagnostic process, not just the technical sequencing, and broadens the scope to include family members when clinically relevant.
The coverage for WGS/WES is specified 'as a first-tier test' for eligible individuals.
Section 2(a)(1)(B), new paragraph (5)
Why it matters:This is a standard legislative technique to provide a clinical guideline for appropriate utilization directly within the coverage mandate, rather than in separate guidance.
Case for: Proponents argue that designating WGS/WES as a 'first-tier test' is crucial for maximizing its diagnostic utility, allowing for earlier and more efficient diagnosis by avoiding a lengthy series of less comprehensive tests. This can significantly shorten the diagnostic odyssey.
Case against: Some critics might argue that 'first-tier' could be interpreted too broadly, leading to over-utilization, or too narrowly, limiting access. They might prefer more detailed clinical guidelines to be developed by medical experts rather than a broad legislative designation.
Estimated impact: This designation aims to shift WGS/WES from a test of last resort to an early diagnostic tool, potentially transforming the diagnostic pathway for many children.
The amendments made by this section shall apply beginning January 1, 2027.
Section 2(e)
Why it matters:This is standard legislative practice to specify the implementation timeline, allowing agencies and states time to prepare for the new requirements.
Case for: Supporters argue that a delayed effective date provides necessary time for states to update their Medicaid plans, adjust payment systems, and for HHS to develop initial guidance and outreach materials, ensuring a smoother transition.
Case against: Critics might argue that delaying implementation means children will continue to face diagnostic barriers for another year, prolonging suffering and potentially increasing costs that could be avoided with earlier diagnosis.
Estimated impact: Provides a clear timeline for implementation, allowing for preparatory work but also delaying the direct benefits of the bill for approximately one year from the likely enactment date.